Download PDF
Semin Thromb Hemost 2021; 47(08): 962-971
DOI: 10.1055/s-0041-1733925
Review Article

Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand?

Anna Falanga
1   Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
2   Department of Medicine and Surgery, University of Milan Bicocca, Milan, Italy
,
Marina Marchetti
1   Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
,
Laura Russo
1   Division of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
› Author Affiliations Funding The HYPERCAN study (ClinicalTrials.gov # NCT0262281) is funded by AIRC “5xMILLE” n. 12237 grant from the “Italian Association for Cancer Research (AIRC).”
› Further Information
    Permissions and Reprints

Abstract

Cancer patients are characterized by hypercoagulable state and an increased rate of thrombotic events, the most common being venous thromboembolism. Several hemostatic pathways that are significantly implicated in mechanisms of thromboembolic disease are also involved in growth, invasion, and metastatic spread of malignant cells as well in tumor-induced neo-angiogenesis. This close connection between cancer and the hemostatic system has prompted numerous studies on the role of alterations in the level plasma biomarkers of the different compartments of hemostasis in predicting cancer prognosis. In this review, we collect the results of several exemplificative studies that have evaluated clotting activation biomarkers in relation to different cancer outcomes with a final emphasis on current research and forthcoming directions in this field.

Keywords

cancer - hypercoagulable state - tumor cell - hemostatic system - biomarkers - fibrinogen - plasminogen activator inhibitor - D-dimer - fibrinogen - cellular microparticles - thrombin - neutrophil extracellular traps - mortality - plasminogen activator - disease recurrence - disease progression


Publication History

Article published online:
27 August 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013; 11 (02) 223-233
    CrossrefPubMedGoogle Scholar
  • 2 Shoji M, Hancock WW, Abe K. et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152 (02) 399-411
    PubMedGoogle Scholar
  • 3 Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res 2015; 135 (Suppl. 01) S8-S11
    CrossrefPubMedGoogle Scholar
  • 4 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
    CrossrefPubMedGoogle Scholar
  • 5 Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res 2014; 133 (Suppl. 02) S35-S38
    CrossrefPubMedGoogle Scholar
  • 6 Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie 2012; 32 (02) 115-125
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 2009; 22 (01) 49-60
    CrossrefPubMedGoogle Scholar
  • 8 Adams GN, Rosenfeldt L, Frederick M. et al. Colon cancer growth and dissemination relies upon thrombin, stromal PAR-1, and fibrinogen. Cancer Res 2015; 75 (19) 4235-4243
    CrossrefPubMedGoogle Scholar
  • 9 Rak J, Milsom C, Magnus N, Yu J. Tissue factor in tumour progression. Best Pract Res Clin Haematol 2009; 22 (01) 71-83
    CrossrefPubMedGoogle Scholar
  • 10 Rickles FR, Falanga A. Activation of clotting factors in cancer. Cancer Treat Res 2009; 148: 31-41
    CrossrefPubMedGoogle Scholar
  • 11 Zhang PP, Sun JW, Wang XY, Liu XM, Li K. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. Eur J Surg Oncol 2013; 39 (09) 951-956
    CrossrefPubMedGoogle Scholar
  • 12 Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97 (12) 3044-3052
    CrossrefPubMedGoogle Scholar
  • 13 Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997; 52 (06) 563-565
    CrossrefPubMedGoogle Scholar
  • 14 Komurcuoglu B, Ulusoy S, Gayaf M, Guler A, Ozden E. Prognostic value of plasma D-dimer levels in lung carcinoma. Tumori 2011; 97 (06) 743-748
    CrossrefPubMedGoogle Scholar
  • 15 Chen Y, Yu H, Wu C. et al. Prognostic value of plasma D-dimer levels in patients with small-cell lung cancer. Biomed Pharmacother 2016; 81: 210-217
    CrossrefPubMedGoogle Scholar
  • 16 Altiay G, Ciftci A, Demir M. et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol) 2007; 19 (07) 494-498
    CrossrefPubMedGoogle Scholar
  • 17 Zhu LR, Li J, Chen P, Jiang Q, Tang XP. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients. Clin Transl Oncol 2016; 18 (02) 178-188
    CrossrefPubMedGoogle Scholar
  • 18 Moik F, Zöchbauer-Müller S, Posch F, Pabinger I, Ay C. Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer. Cancers (Basel) 2020;12(06):
    Google Scholar
  • 19 Ma X, Li Y, Zhang J, Huang J, Liu L. Prognostic role of D-dimer in patients with lung cancer: a meta-analysis. Tumour Biol 2014; 35 (03) 2103-2109
    CrossrefPubMedGoogle Scholar
  • 20 Zhou YX, Yang ZM, Feng J, Shan YJ, Wang WL, Mei YQ. High plasma D-dimer level is associated with decreased survival in patients with lung cancer: a meta-analysis. Tumour Biol 2013; 34 (06) 3701-3704
    CrossrefPubMedGoogle Scholar
  • 21 Zhang Y, Cao J, Deng Y. et al. Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer. Clinics (São Paulo) 2020; 75: e993
    CrossrefPubMedGoogle Scholar
  • 22 Hong T, Shen D, Chen X, Wu X, Hua D. Preoperative plasma fibrinogen, but not D-dimer might represent a prognostic factor in non-metastatic colorectal cancer: A prospective cohort study. Cancer Biomark 2017; 19 (01) 103-111
    CrossrefPubMedGoogle Scholar
  • 23 Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001; 31 (08) 388-394
    CrossrefPubMedGoogle Scholar
  • 24 Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol 2010; 102 (05) 428-432
    CrossrefPubMedGoogle Scholar
  • 25 Lee S, Huh SJ, Oh SY. et al. Clinical significance of coagulation factors in operable colorectal cancer. Oncol Lett 2017; 13 (06) 4669-4674
    CrossrefPubMedGoogle Scholar
  • 26 Blackwell K, Hurwitz H, Liebérman G. et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004; 101 (01) 77-82
    CrossrefPubMedGoogle Scholar
  • 27 Kilic M, Yoldas O, Keskek M. et al. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis 2008; 10 (03) 238-241
    CrossrefPubMedGoogle Scholar
  • 28 Motavaf E, Sunesen KG, Stender MT, Thorlacius-Ussing O. Prognostic value of preoperative D-dimer and carcinoembryonic antigen levels in patients undergoing intended curative resection for colorectal cancer: a prospective cohort study. Int J Colorectal Dis 2014; 29 (11) 1427-1432
    CrossrefPubMedGoogle Scholar
  • 29 Pedrazzani C, Cerullo G, Marrelli D. et al. Is circulating D-dimer level a better prognostic indicator than CEA in resectable colorectal cancer? Our experience on 199 cases. Int J Biol Markers 2010; 25 (03) 171-176
    CrossrefPubMedGoogle Scholar
  • 30 Lu SL, Ye ZH, Ling T. et al. High pretreatment plasma D-dimer predicts poor survival of colorectal cancer: insight from a meta-analysis of observational studies. Oncotarget 2017; 8 (46) 81186-81194
    CrossrefPubMedGoogle Scholar
  • 31 Pedrazzani C, Mantovani G, Salvagno GL. et al. Elevated fibrinogen plasma level is not an independent predictor of poor prognosis in a large cohort of Western patients undergoing surgery for colorectal cancer. World J Gastroenterol 2016; 22 (45) 9994-10001
    CrossrefPubMedGoogle Scholar
  • 32 Lee JH, Hyun JH, Kim DY. et al. The role of fibrinogen as a predictor in preoperative chemoradiation for rectal cancer. Ann Surg Oncol 2015; 22 (01) 209-215
    CrossrefPubMedGoogle Scholar
  • 33 Li M, Wu Y, Zhang J, Huang L, Wu X, Yuan Y. Prognostic value of pretreatment plasma fibrinogen in patients with colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (37) e16974
    CrossrefPubMedGoogle Scholar
  • 34 Ay C, Dunkler D, Pirker R. et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97 (08) 1158-1164
    CrossrefPubMedGoogle Scholar
  • 35 Moik F, Posch F, Grilz E. et al. Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. Thromb Res 2020; 187: 9-17
    CrossrefPubMedGoogle Scholar
  • 36 Lee JH, Ryu KW, Kim S, Bae JM. Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology 2004; 51 (60) 1860-1863
    PubMedGoogle Scholar
  • 37 Liu L, Zhang X, Yan B. et al. Elevated plasma D-dimer levels correlate with long term survival of gastric cancer patients. PLoS One 2014; 9 (03) e90547
    CrossrefPubMedGoogle Scholar
  • 38 Yu X, Hu F, Yao Q, Li C, Zhang H, Xue Y. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study. BMC Cancer 2016; 16: 480
    CrossrefPubMedGoogle Scholar
  • 39 Blackwell K, Haroon Z, Broadwater G. et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18 (03) 600-608
    CrossrefPubMedGoogle Scholar
  • 40 Wen J, Yang Y, Ye F. et al. The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment. Breast 2015; 24 (06) 745-750
    CrossrefPubMedGoogle Scholar
  • 41 Krenn-Pilko S, Langsenlehner U, Stojakovic T. et al. An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients. Breast 2015; 24 (05) 667-672
    CrossrefPubMedGoogle Scholar
  • 42 Liu YL, Lu Q, Liang JW. et al. High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer. Medicine (Baltimore) 2015; 94 (05) e481
    CrossrefPubMedGoogle Scholar
  • 43 Man YN, Wang YN, Hao J. et al. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. Int J Gynecol Cancer 2015; 25 (01) 24-32
    CrossrefPubMedGoogle Scholar
  • 44 Sakurai M, Satoh T, Matsumoto K. et al. High pretreatment plasma D-dimer levels are associated with poor prognosis in patients with ovarian cancer independently of venous thromboembolism and tumor extension. Int J Gynecol Cancer 2015; 25 (04) 593-598
    CrossrefPubMedGoogle Scholar
  • 45 Zhao K, Deng H, Qin Y, Liao W, Liang W. Prognostic significance of pretreatment plasma fibrinogen and platelet levels in patients with early-stage cervical cancer. Gynecol Obstet Invest 2015; 79 (01) 25-33
    CrossrefPubMedGoogle Scholar
  • 46 Yamada Y, Kawaguchi R, Iwai K. et al. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer. J Obstet Gynaecol 2020; 40 (01) 102-106
    CrossrefPubMedGoogle Scholar
  • 47 Liu P, Wang Y, Tong L. et al. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients. Cancer Chemother Pharmacol 2015; 76 (06) 1163-1171
    CrossrefPubMedGoogle Scholar
  • 48 Xu L, He F, Wang H, Gao B, Wu H, Zhao S. A high plasma D-dimer level predicts poor prognosis in gynecological tumors in East Asia area: a systematic review and meta-analysis. Oncotarget 2017; 8 (31) 51551-51558
    CrossrefPubMedGoogle Scholar
  • 49 Wu J, Fu Z, Liu G, Xu P, Xu J, Jia X. Clinical significance of plasma D-dimer in ovarian cancer: a meta-analysis. Medicine (Baltimore) 2017; 96 (25) e7062
    CrossrefPubMedGoogle Scholar
  • 50 Shu YJ, Weng H, Bao RF. et al. Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. BMC Cancer 2014; 14: 566
    CrossrefPubMedGoogle Scholar
  • 51 Erdem S, Amasyali AS, Aytac O, Onem K, Issever H, Sanli O. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics. Urol Oncol 2014; 32 (07) 1031-1040
    CrossrefPubMedGoogle Scholar
  • 52 Falanga A, Marchetti M, Massi D. et al. Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. J Am Acad Dermatol 2016; 74 (06) 1254-1256.e4
    CrossrefPubMedGoogle Scholar
  • 53 Liu R, Zheng S, Yuan Q. et al. The prognostic significance of combined pretreatment fibrinogen and neutrophil-lymphocyte ratio in various cancers: a systematic review and meta-analysis. Dis Markers 2020; 2020: 4565379
    PubMedGoogle Scholar
  • 54 Mengele K, Napieralski R, Magdolen V. et al. Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010; 10 (07) 947-962
    CrossrefPubMedGoogle Scholar
  • 55 Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 2014; 16 (04) 428
    CrossrefPubMedGoogle Scholar
  • 56 Duffy MJ, Harbeck N, Nap M. et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017; 75: 284-298
    CrossrefPubMedGoogle Scholar
  • 57 Dovnik NF, Takac I. Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients. Radiol Oncol 2016; 51 (01) 65-73
    CrossrefPubMedGoogle Scholar
  • 58 Stephens RW, Nielsen HJ, Christensen IJ. et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91 (10) 869-874
    CrossrefPubMedGoogle Scholar
  • 59 Fernebro E, Madsen RR, Fernö M. et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001; 37 (04) 486-491
    CrossrefPubMedGoogle Scholar
  • 60 Riisbro R, Christensen IJ, Nielsen HJ. et al. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers 2005; 20 (02) 93-102
    CrossrefPubMedGoogle Scholar
  • 61 Riisbro R, Stephens RW, Brünner N. et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 2001; 82 (03) 523-531
    CrossrefPubMedGoogle Scholar
  • 62 Ferroni P, Roselli M, Portarena I. et al. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. Anticancer Res 2014; 34 (03) 1153-1161
    PubMedGoogle Scholar
  • 63 Versteeg HH. Tissue factor: old and new links with cancer biology. Semin Thromb Hemost 2015; 41 (07) 747-755
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression and angiogenesis. Thromb Res 2010; 125 (Suppl. 02) S36-S38
    CrossrefPubMedGoogle Scholar
  • 65 Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008; 34 (02) 204-210
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83 (02) 164-170
    CrossrefPubMedGoogle Scholar
  • 67 Tieken C, Verboom MC, Ruf W. et al. Tissue factor associates with survival and regulates tumour progression in osteosarcoma. Thromb Haemost 2016; 115 (05) 1025-1033
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. Thromb Res 2012; 129 (Suppl. 01) S132-S136
    CrossrefPubMedGoogle Scholar
  • 69 Marchetti M, Tartari CJ, Russo L. et al. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol 2014; 89 (01) 68-73
    CrossrefPubMedGoogle Scholar
  • 70 Garnier D, Magnus N, D'Asti E. et al. Genetic pathways linking hemostasis and cancer. Thromb Res 2012; 129 (Suppl. 01) S22-S29
    CrossrefPubMedGoogle Scholar
  • 71 Claussen C, Rausch AV, Lezius S. et al. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer. Thromb Res 2016; 141: 39-48
    CrossrefPubMedGoogle Scholar
  • 72 Bharthuar A, Khorana AA, Hutson A. et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013; 132 (02) 180-184
    CrossrefPubMedGoogle Scholar
  • 73 Thaler J, Ay C, Mackman N. et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest 2013; 43 (03) 277-285
    CrossrefPubMedGoogle Scholar
  • 74 Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9 (04) 458-462
    CrossrefPubMedGoogle Scholar
  • 75 Unruh D, Sagin F, Adam M. et al. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype. Ann Surg Oncol 2015; 22 (Suppl. 03) S1206-S1211
    CrossrefPubMedGoogle Scholar
  • 76 Kocatürk B, Van den Berg YW, Tieken C. et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad Sci U S A 2013; 110 (28) 11517-11522
    CrossrefPubMedGoogle Scholar
  • 77 Kocatürk B, Tieken C, Vreeken D. et al. Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression. J Thromb Haemost 2015; 13 (09) 1683-1693
    CrossrefPubMedGoogle Scholar
  • 78 Amirkhosravi A, Meyer T, Amaya M. et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007; 33 (07) 643-652
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Zhai LL, Cai CY, Wu Y, Tang ZG. Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma. Int J Clin Exp Pathol 2015; 8 (01) 682-691
    PubMedGoogle Scholar
  • 80 Xu C, Wang H, He H. et al. Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer. BMC Cancer 2013; 13: 118
    CrossrefPubMedGoogle Scholar
  • 81 Wang S, Xiao X, Zhou X. et al. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010; 10: 617
    CrossrefPubMedGoogle Scholar
  • 82 Wu D, Xiong L, Wu S, Jiang M, Lian G, Wang M. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Lung Cancer 2012; 76 (01) 106-111
    CrossrefPubMedGoogle Scholar
  • 83 Balasenthil S, Huang Y, Liu S. et al. A plasma biomarker panel to identify surgically resectable early-stage pancreatic cancer. J Natl Cancer Inst 2017; 109 (08) djw341
    CrossrefPubMedGoogle Scholar
  • 84 Luengo-Gil G, Calvo MI, Martín-Villar E. et al. Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase. Sci Rep 2016; 6: 27544
    CrossrefPubMedGoogle Scholar
  • 85 Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004; 98 (02) 93-98
    CrossrefPubMedGoogle Scholar
  • 86 Koh SC, Khalil R, Lim FK, Ilancheran A, Choolani M. The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 2006; 12 (01) 3-8
    CrossrefPubMedGoogle Scholar
  • 87 Wilts IT, Hutten BA, Meijers JCM, Spek CA, Büller HR, Kamphuisen PW. Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer. Thromb Res 2017; 154: 1-6
    CrossrefPubMedGoogle Scholar
  • 88 Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood 2014; 124 (10) 1553-1562
    CrossrefPubMedGoogle Scholar
  • 89 Ruf W, Schaffner F. Role of the protein C receptor in cancer progression. Thromb Res 2014; 133 (Suppl. 02) S85-S89
    CrossrefPubMedGoogle Scholar
  • 90 Thålin C, Lundström S, Seignez C. et al. Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer. PLoS One 2018; 13 (01) e0191231
    CrossrefPubMedGoogle Scholar
  • 91 Garley M, Jabłońska E, Dąbrowska D. NETs in cancer. Tumour Biol 2016; 37 (11) 14355-14361
    CrossrefPubMedGoogle Scholar
  • 92 Yang C, Sun W, Cui W. et al. Procoagulant role of neutrophil extracellular traps in patients with gastric cancer. Int J Clin Exp Pathol 2015; 8 (11) 14075-14086
    PubMedGoogle Scholar
  • 93 Demers M, Krause DS, Schatzberg D. et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012; 109 (32) 13076-13081
    CrossrefPubMedGoogle Scholar
  • 94 Abdol Razak N, Elaskalani O, Metharom P. Pancreatic cancer-induced neutrophil extracellular traps: a potential contributor to cancer-associated thrombosis. Int J Mol Sci 2017; 18 (03) E487
    CrossrefPubMedGoogle Scholar
  • 95 Leal AC, Mizurini DM, Gomes T. et al. Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci Rep 2017; 7 (01) 6438
    CrossrefPubMedGoogle Scholar
  • 96 Li B, Liu Y, Hu T. et al. Neutrophil extracellular traps enhance procoagulant activity in patients with oral squamous cell carcinoma. J Cancer Res Clin Oncol 2019; 145 (07) 1695-1707
    CrossrefPubMedGoogle Scholar
  • 97 Rosell A, Aguilera K, Hisada Y. et al. Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer. Sci Rep 2021; 11 (01) 5074
    CrossrefPubMedGoogle Scholar
  • 98 D'Alessio A, Marchetti M, Tartari CJ. et al. Long term low molecular weight heparin anticoagulant therapy modulates thrombin generation and D-dimer in patients with cancer and venous thromboembolism. Cancer Invest 2017; 35 (07) 490-499
    CrossrefPubMedGoogle Scholar
  • 99 Marchetti M, Castoldi E, Spronk HM. et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008; 112 (10) 4061-4068
    CrossrefPubMedGoogle Scholar
  • 100 Reitter EM, Kaider A, Ay C. et al. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. J Thromb Haemost 2016; 14 (02) 294-305
    CrossrefPubMedGoogle Scholar
  • 101 Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM. Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 2008; 6 (09) 1482-1487
    CrossrefPubMedGoogle Scholar
  • 102 Abu Saadeh F, Langhe R, Galvin DM. et al. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. Thromb Res 2016; 139: 135-141
    CrossrefPubMedGoogle Scholar
  • 103 Leiba M, Malkiel S, Budnik I. et al. Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. Blood Cells Mol Dis 2017; 65: 1-7
    CrossrefPubMedGoogle Scholar
  • 104 Ay C, Dunkler D, Simanek R. et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29 (15) 2099-2103
    CrossrefPubMedGoogle Scholar
  • 105 Roselli M, Ferroni P, Riondino S. et al. Impact of chemotherapy on activated protein C-dependent thrombin generation—association with VTE occurrence. Int J Cancer 2013; 133 (05) 1253-1258
    CrossrefPubMedGoogle Scholar
  • 106 Tinholt M, Viken MK, Dahm AE. et al. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer 2014; 14: 845
    CrossrefPubMedGoogle Scholar
  • 107 Gezelius E, Flou Kristensen A, Bendahl PO. et al. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: a sub-study of RASTEN—a randomized trial with low molecular weight heparin. PLoS One 2018; 13 (11) e0207387
    CrossrefPubMedGoogle Scholar
  • 108 Falanga A, Santoro A, Labianca R. et al; HYPERCAN Study Group. Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. Thromb Res 2016; 140 (Suppl. 01) S55-S59
    CrossrefPubMedGoogle Scholar
  • 109 Giaccherini C, Marchetti M, Masci G. et al; HYPERCAN Investigators. Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. Haematologica 2020; 105 (06) 1704-1711
    CrossrefPubMedGoogle Scholar
  • 110 Marchetti M, Giaccherini C, Masci G. et al; HYPERCAN Investigators. Thrombin generation predicts early recurrence in breast cancer patients. J Thromb Haemost 2020; 18 (09) 2220-2231
    CrossrefPubMedGoogle Scholar
  • 111 Gomez-Rosas P, Pesenti M, Verzeroli C. et al; HYPERCAN Investigators. Validation of the role of thrombin generation potential by a fully automated system in the identification of breast cancer patients at high risk of disease recurrence. TH Open 2021; 5 (01) e56-e65
    Article in Thieme ConnectPubMedGoogle Scholar